In the News
ANNOUNCING NEW LECTURESHIP SERIES
Urology, in conjunction with The Leo & Anne Albert Charitable Trust, is proud to announce the inaugural Anne Albert Bladder Cancer Lectureship Series. The forum will be held Saturday, April 1, 2017. Learn more.
435 MAGAZINE TOP DOCTORS
Be sure to check out the January 2017 issue of 435 Magazine. Drs. Griebling, Nangia, Holzbeirlein, Thrasher and Duchene are 5 of the 6 top urologists featured. A great honor!
FERTILITY PRESERVATION VIDEO FEATURING DR. NANGIA
The Urology Care Foundation's video called "Fertility Preservation for Adolescents and Men Starting Cancer Treatment" features Dr. Ajay Nangia on the importance of considering sperm banking when facing a cancer diagnosis.
Congratulations to Dr. Tomas Griebling for being recognized by the American Urological Association as a recipient of their Distinguished Service Award for years of outstanding service in educating and research the field of geriatric urology. Read more.
RECOGNIZED AS A TOP DOCTOR
Congratulations to Dr. David Duchene for being named one of Ingram's 2016 Top Doctors! "Duchene has developed a reputation as a skilled operator using technologies that are advancing rapidly. His specialty is a leader among surgical fields in the adoption of laparoscopy, robotic surgery and thermal ablation technology." (Ingram's, September 2016)
WELCOME NEW LEADERSHIP
A big congratulations to Dr. Jeffrey Holzbeierlein who was recently named the new Professor and John W. Weigel Interim Chair! He follows the successful tenure of Dr. J. Brantley Thrasher. Thank you, Dr. Thrasher, for your dedicated service.
Other position transitions:
- Dr. Ajay Nangia will serve as Vice Chair of Urology.
- Dr. Tomas L. Griebling is now the Senior Associate Dean of Medical Education.
- Dr. Moben Mirza has been named Residency Program Director.
LEADING THE NATION
Our urologists regularly serve in leadership positions within the national and international medical communities. These include:
THE RANKINGS ARE IN: UROLOGY AMONG THE TOP IN THE NATION
The urology team at the University of Kansas Hospital ranked #17
in the nation according to U.S. News and World Report
. The ranking is based on various data categories, including volume of high-risk patients, nurse staffing and patient survival. Learn more about this distinction
Dr. Moben Mirza is yet another faculty member to enter the American Urological Association (AUA) Leadership Program.
Dr. Tomas Griebling has been promoted to Senior Associate Dean of Education for the University of Kansas School of Medicine.
SEVEN UROLOGISTS NAMED KANSAS CITY'S BEST DOCTORS BY 435 MAGAZINE
Congratulations to the following doctors for being named Kansas City's Best Doctors by 435 Magazine (as chosen by their peers): Drs. Duchene, Griebling, Holzbeierlein, Mirza, Nangia, Thrasher and Wyre.
PRESTIGIOUS NEW APPOINTMENT
Dr. Brantley Thrasher has been elected to the Clinical Society of Genitorurinary Surgeons. This is considered one of the most prestigious societies in the field, with active membership limited to 25 of the top academic urologists in the U.S. Read more.
A JOB WELL DONE
Dr. Ajay Nangia recently finished his role as President of the Society for the Study of Male Reproduction and Urology (SMRU), a sub-society of the American Society of Reproductive Medicine (ASRM).
Funded by the NIH, a new trial for hormonal male contraception will begin next year. The Urology Department is a satellite site in a partnership with UCLA.
NEW LEADERSHIP POST
Dr. Jeffrey Holzbeierlein is now the President of the South Central Section of the American Urological Association. Read more.
FACULTY NAMED TOP UROLOGISTS 2014-2015 BY KANSAS CITY BUSINESS JOURNAL
Drs. Thrasher, Holzbeierlein, Duchene and Nangia were named as best urologists in the Kansas City area. Only six were named. We are proud that four out of the six came from the University of Kansas Medical Center.
DR. NANGIA PRESENTS AT THE FDA HEARING ON TESTOSTERONE
In Sept 2014, the FDA held an advisory committee on the use of testosterone and the possible cardiovascular risk. Dr. Nangia represented the American Urological Association, or AUA, and the Sexual Medicine Society of North America in delivering the statement. For more details on the AUA's position statement on testosterone, click here.
The FDA reviewed the indications for the use of testosterone with questions about the benefits of testosterone not being clear, especially when given to men with low testosterone that was potentially age related only and not a known health condition. The unclear nature of testosterone and possible cardiovascular risk was discussed and, since there was some evidence, even though with significant methodological issues, they coulld not ignore that there was a "weak signal" of evidence and, as such, could not ignore it and suggested that possible warning of the risk be added to the product label. The concern is that without proper testing, monitoring and evaluation of benefits, testosterone use may be overused. Twenty-five percent of men currently on testosterone have not even had a testosterone level checked.
The issue goes to the FDA for final ruling.
U.S. NEWS AND WORLD REPORT RANKS US ONE OF THE TOP UROLOGY PRACTICES IN THE COUNTRY
The 2014-2015 U.S. News and World Report ranked us in the top 50 urology practices in the country based on patient safety and several other important practice determinations. This highlights what we stand for: local, regional and national excellence in patient care; complexity of care; nationally ranked specialization in all aspects of urology. We pride ourselves on being leaders in the field of urology and setting standards.
UROLOGISTS FROM THE UNIVERSITY OF KANSAS MEDICAL CENTER TALK ON SIRUISXM RADIO
Drs. Griebling and Nangia recently talked on Men's Health Show on SiriusXM's Doctor Radio. Dr. Griebling discussed the recent study by the CDC stating that older men and women are prone to urinary incontinence.
Dr. Nangia spoke about his meeting at the White House on President Obama's initiative for young men, "My Brother's Keeper."
A CONTINUED TRADITION OF LEADERSHIP IN UROLOGY
FOR IMMEDIATE RELEASE: May 30, 2014
Contact: Christine Frey, AUA 410-999-7091, cfrey@AUAnet.org
American Urological Association Announces David A. Duchene, MD, to the 2014-2015 Class of Future Leaders.
Linthicum, MD, May 30, 2014 – During its 109th Annual Scientific Meeting in Orlando, the American Urological Association, or AUA, officially launched the AUA Leadership Program’s sixth class by announcing David A. Duchene, MD, as one of 20 urologists who will be taking part in the program over the next year.
The year-long program is designed to enable urologists to participate in strategic leadership events; network with peers; gain an inside look into the AUA governance and have an opportunity to serve the profession in a leadership capacity.
Dr. Duchene is an Associate Professor of Urology at the University of Kansas Medical Center and the Director of Minimally-Invasive Urological Surgery and Kidney Stone Disease. He previously completed urology residency training at the University of Texas Southwestern Medical Center and then finished an Endourological Society fellowship at the University of Iowa Hospitals and Clinics. Dr. Duchene is currently the president of the Kansas Urological Society. He also serves as the section editor for “New Technologies in Endourology” Section of the Journal of Endourology. Dr. Duchene has written several peer-reviewed journal articles and text book chapters in the field of urology and serves as a reviewer for multiple publications, including The Journal of Urology®, Urology, and the Journal of Endourology.
Upon completion of the program, Dr. Duchene will have an opportunity to become more active in the AUA at the national and Section levels.
“This very successful program has enabled a number of very talented young urologists to assume leadership positions in the AUA at an earlier career stage,” said William W. Bohnert, MD, AUA President. “These individuals have brought fresh ideas, new approaches and significant energy to the Association.”
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 20,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
LEADING THE WAY WITH CUTTING EDGE CLINICAL PRACTICE AND RESEARCH
Our urologists continue to stand out in the region, advancing clinical practice and research with the following work to be presented at the national meeting.
Authors: Marcus Austenfeld and Ajay Nangia. Abstract Title: Useful Waste: A History of the Industrial Application of Urine.
Authors: Zach Hamilton, Joshua Griffin, Moben Mirza, Jeff Holzbeierlein. Abstract Title: The Role of Alvimophan for Radical Cystectomy.
Authors: Zach Hamilton, Ruibao Chen, Xiangxing Kuang, Yiling Huang, J. Brantley Thrasher and Benyi Li. Abstract Title: SMYD3 is Responsible for Androgen-Induced H3K4 Methylation in Prostate Cancer Cells.
Authors: Daniel Zainfeld, Seema Dubey, Jo Wick, Jeffrey Holzbeierlein, Peter Van Veldhuizen, Brantley Thrasher, Dev Karan. Abstract Title: Applicability of Macrophage Inhibitory Cytokine as a Potential Biomarker for Racial Disparity in Prostate Cancer.
Authors: Michael Aberger, Bradley Wilson, Tomas Griebing, Jeffrey Holzbeierlein and Ajay Nangia. Abstract Title: Testicular Self-Examinations: A Cost Analysis.
Authors: Michael Aberger, Bradley Wilson, Andrew Arther, Tomas Griebling, Priya Padmanabhan. Abstract Title: Botulinum Toxin A: The Shift to a Minimally Invasive Management of Neurogenic Bladder.
Michael Aberger, Will Parker, Priya Padmanabhan. The Value of Retropubic Slings Following Failed Prior Anti-Incontinence Procedures.
SEXUAL MEDICINE SOCIETY OF NORTH AMERICA, OR SMSNA, HAS COME OUT WITH A POSITION STATEMENT ABOUT TESTOSTERONE AND CARDIOVASCULAR RISK
The SMSNA, a sub-specialty society within the American Urological Association reviews the concerns about cardiovascular risk from testosterone use in more detail.
AMERICAN UROLOGICAL ASSOCIATION RELEASES A POSITION STATEMENT ON THE TREATMENT OF TESTOSTERONE DEFICIENCY ("LOW T") AND RISKS
Testosterone use in the USA has increased dramatically over the last few years. There are some important ways to diagnose and treat testosterone deficiency and a lot has been discussed on the cardiovascular risk of treatment. The data/literature on the risk is not clear as suggested. Dr. Nangia was on an AUA advisory panel that has come out with a position statement on the issues and has been reviewed with a number of societies involved in care of these patients. Refer to the statement.
DR. TOMAS GRIEBLING NAMED ASSOCIATE EDITOR OF THE JOURNAL "UROLOGY"
Dr. Griebling will now be responsible for reviewing merit of cutting edge research submitted to the journal "Urology" in a number of sub-specialty topics. This prestigious position is another example of how Dr. Griebling and our other physicians are respected leaders and providers in the field of Urology, in Kansas City, the Midwest region and nationally.
BLUE LIGHT TECHNOLOGY TO IDENTIFY BLADDER CANCER
Dr. Mirza is spearheading the effort to use Blue Light technology to identify carcinoma in situ, a flat type of bladder cancer that can be difficult to see with regular visualization of the bladder.
BEST DOCTORS IN AMERICA 2014 RECOGNIZES FOUR UROLOGISTS FROM THE UNIVERSITY OF KANSAS MEDICAL CENTER
Four out of six urologists in the Kansas City metro area recognized by Best Doctors in America 2014 are from the University of Kansas Medical Center. We congratulate Drs. Thrasher, Holzbeierlein, Duchene and Nangia.
DR. NANGIA TALKS ABOUT THE DOWNSIDE OF USING TESTOSTERONE FOR MEN'S HEALTH ON FOX 4 NEWS KC
The cause for low testosterone needs to be investigated, including lifestyle and other issues such as sleep disturbances and obesity. Medications can lower testosterone levels. All this needs to be investigated as part of men's health. Lab work with confirmation of a low testosterone needs to be performed and, if testosterone is considered an option, then close monitoring of symptoms and blood work is needed. The issue of low testosterone is not just about "a number".
Dr. Nangia reports on the negative effect of testosterone on men in their reproductive years and causing infertility.
FACULTY MEMBER MANAGING COMPLEX URINARY INCONTINENCE AND ARTIFICIAL URINARY SPHINCTER ISSUES
Dr. Broghammer has one of the largest practices in this condtion and continues to publish his surgical findings:
Paul Guidos, Christopher Powell, William Brant, Joshua Broghammer. Outcomes of artificial urinary sphincter placement in high-risk patients as compared to average risk patients. A multi-institutional study. South Central Section of the American Urological Association Annual Meeting. 2013.
BOTOX CAN BE USED IN THE BLADDER. RESEARCHERS AT THE UNIVERSITY OF KANSAS MEDICAL CENTER HAVE STUDIED THIS RECENTLY.
Prospective Quality of Life Follow-up of Botulinum Toxin A for Urinary Incontinence
Dr. Andrew R. Arther, Dr. William P. Parker, Dr. Bradley Wilson, Dr. Katie Murray, Dr. Priya Padmanabhan
Introduction: The FDA approved Botulinum toxin A for the treatment of neurogenic detrusor overactivity and overactive bladder. Multiple studies have shown its effectiveness in neurogenic bladders and for overactive bladder with durable improvements in incontinence episodes and urodynamic parameters. Prospective data is limited on the improvements Botulinum toxin A has made in the quality of life of these patients. We report preliminary quality of life follow up in our cohort of Botulinum toxin A patients.
Conclusions: This was a prospective review of the effect Botulinum toxin A has on quality of life for overactive bladder and neurogenic bladder patients. Overactive bladder patients had more durable improvements in their quality of life. Further study to provide longer follow-up will help in counseling patients on reasonable expectations.
ROBOTIC SURGERY FOR KIDNEY CANCER REDUCES LENGTH OF STAY
ROBOTIC PARTIAL NEPHRECTOMY IS ASSOCIATED WITH DECREASED LENGTH OF STAY AND LESS BLOOD LOSS
Zach Hamilton, MD, Margaret Le, MD, Kahlil Saad, David Duchene, MD, Jeffrey Holzbeierlein, MD, Moben Mirza, MD, The University of Kansas Medical Center
Background: An estimated 60,000 cases of kidney cancer will be diagnosed in the U.S. each year. Standard of care for small renal masses has transitioned to partial nephrectomy with strong data to support oncologic outcomes and preservation of renal function. Laparoscopic techniques are favorable when compared to open, but outcomes in robotics are still gaining data.
Goal: Perform a review of outcomes for open, laparoscopic, and robotic partial nephrectomy.
Methods: A retrospective review of partial nephrectomies from 2006 through 2012 at Kansas University Medical Center was performed. Only solitary masses for suspected renal carcinoma were included. Nephrometry scores were calculated when available.
Conclusion: For partial nephrectomy, estimated blood loss is significantly lower with robotics as compared to open. Length of stay is decreased with robotics when compared to open. There are no significant differences between laparoscopics or robotics, indicating robotics appears safe and effective. When compared to open surgery, robotic partial nephrectomy seems to afford the advantage of decreased blood loss and decreased length of stay.
UROLOGY FACULTY NAMED AS TOP UROLOGISTS IN KANSAS CITY BUSINESS JOURNAL FOR 2012-2013
The Dept. of Urology was again recognized by the U.S. News and World Report as providing the best urological care in Kansas City and Kansas. This is based on a number of criteria. Click here for details.